UVI5008: the first reversible, non-covalent Bruton’s tyrosine kinase epi-inhibitor for B-cell malignancies

Abstract Background Chronic lymphocytic leukemia (CLL) can still be a therapeutic challenge; notwithstanding substantial progress in therapeutic approaches with small molecule inhibitors, the emergence of inhibitor resistance and suboptimal long-term outcomes highlight the persistent need for novel,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Carmela Dell’Aversana, G. Sgueglia, C. Massaro, U. Perricone, F. Sarno, W. L. Megchelenbrink, M. Conte, V. Carafa, A. Campanella, M. Frenquelli, J. Bordini, P. Ghia, V. B. Petrizzi, R. Alvarez, D. Nappi, F. Chiurazzi, F. P. Tambaro, W. G. Wierda, A. R. de Lera, Lucia Altucci
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2026-02-01
Serie:	Journal of Hematology & Oncology
Soggetti:	BTK CLL UVI5008 Epi-inhibitor BTK C481S mutation
Accesso online:	https://doi.org/10.1186/s13045-026-01784-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!